400 related articles for article (PubMed ID: 26645051)
41. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Henson JD; Reddel RR
FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
[TBL] [Abstract][Full Text] [Related]
42. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.
Li F; Wang Y; Hwang I; Jang JY; Xu L; Deng Z; Yu EY; Cai Y; Wu C; Han Z; Huang YH; Huang X; Zhang L; Yao J; Lue NF; Lieberman PM; Ying H; Paik J; Zheng H
bioRxiv; 2023 Feb; ():. PubMed ID: 36798426
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-dependent regulation of telomere maintenance mechanisms: a field as much unexplored as potentially promising.
Santambrogio F; Gandellini P; Cimino-Reale G; Zaffaroni N; Folini M
Curr Pharm Des; 2014; 20(41):6404-21. PubMed ID: 24975607
[TBL] [Abstract][Full Text] [Related]
44. Telomerase-independent paths to immortality in predictable cancer subtypes.
Durant ST
J Cancer; 2012; 3():67-82. PubMed ID: 22315652
[TBL] [Abstract][Full Text] [Related]
45. A novel telomere structure in a human alternative lengthening of telomeres cell line.
Marciniak RA; Cavazos D; Montellano R; Chen Q; Guarente L; Johnson FB
Cancer Res; 2005 Apr; 65(7):2730-7. PubMed ID: 15805272
[TBL] [Abstract][Full Text] [Related]
46. Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
Fujiwara M; Kamma H; Wu W; Yano Y; Homma S; Satoh H
Int J Oncol; 2006 Aug; 29(2):445-51. PubMed ID: 16820888
[TBL] [Abstract][Full Text] [Related]
47. Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies.
Kent T; Gracias D; Shepherd S; Clynes D
Front Oncol; 2019; 9():1518. PubMed ID: 32039009
[TBL] [Abstract][Full Text] [Related]
48. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
49. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
50. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
51. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids.
Perrem K; Bryan TM; Englezou A; Hackl T; Moy EL; Reddel RR
Oncogene; 1999 Jun; 18(22):3383-90. PubMed ID: 10362359
[TBL] [Abstract][Full Text] [Related]
52. Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome.
Jeyapalan JN; Varley H; Foxon JL; Pollock RE; Jeffreys AJ; Henson JD; Reddel RR; Royle NJ
Hum Mol Genet; 2005 Jul; 14(13):1785-94. PubMed ID: 15888482
[TBL] [Abstract][Full Text] [Related]
53. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment.
Jung AR; Yoo JE; Shim YH; Choi YN; Jeung HC; Chung HC; Rha SY; Oh BK
Anticancer Res; 2013 Mar; 33(3):821-9. PubMed ID: 23482750
[TBL] [Abstract][Full Text] [Related]
54. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins.
Potts PR; Yu H
Nat Struct Mol Biol; 2007 Jul; 14(7):581-90. PubMed ID: 17589526
[TBL] [Abstract][Full Text] [Related]
55. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
56. Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.
Deeg KI; Chung I; Bauer C; Rippe K
Front Oncol; 2016; 6():186. PubMed ID: 27602331
[TBL] [Abstract][Full Text] [Related]
57. Assembly of telomeric chromatin to create ALTernative endings.
O'Sullivan RJ; Almouzni G
Trends Cell Biol; 2014 Nov; 24(11):675-85. PubMed ID: 25172551
[TBL] [Abstract][Full Text] [Related]
58. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.
Costa A; Daidone MG; Daprai L; Villa R; Cantù S; Pilotti S; Mariani L; Gronchi A; Henson JD; Reddel RR; Zaffaroni N
Cancer Res; 2006 Sep; 66(17):8918-24. PubMed ID: 16951210
[TBL] [Abstract][Full Text] [Related]
59. Expression of
Idilli AI; Cusanelli E; Pagani F; Berardinelli F; Bernabé M; Cayuela ML; Poliani PL; Mione MC
Front Cell Dev Biol; 2020; 8():65. PubMed ID: 32117990
[TBL] [Abstract][Full Text] [Related]
60. Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells.
Varley H; Pickett HA; Foxon JL; Reddel RR; Royle NJ
Nat Genet; 2002 Mar; 30(3):301-5. PubMed ID: 11919561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
